INFLUENZA-A VIRUS-VACCINES CONTAINING PURIFIED RECOMBINANT H3 HEMAGGLUTININ ARE WELL TOLERATED AND INDUCE PROTECTIVE IMMUNE-RESPONSES IN HEALTHY-ADULTS

被引：90

作者：

POWERS, DC

SMITH, GE

ANDERSON, EL

KENNEDY, DJ

HACKETT, CS

WILKINSON, BE

VOLVOVITZ, F

BELSHE, RB

TREANOR, JJ

机构：

[1] ST LOUIS UNIV,DEPT INTERNAL MED,ST LOUIS,MO

[2] ST LOUIS UNIV,CTR VACCINE DEV,ST LOUIS,MO

[3] MICROGENESYS INC,MERIDEN,CT

[4] UNIV ROCHESTER,INFECT DIS UNIT,ROCHESTER,NY

来源：

JOURNAL OF INFECTIOUS DISEASES | 1995年 / 171卷 / 06期

关键词：

D O I：

10.1093/infdis/171.6.1595

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

This study evaluated the safety, immunogenicity, and protective efficacy of vaccines containing purified recombinant uncleaved hemagglutinin (rHA0) from influenza A/Beijing/32/92 (H3N2) virus. In a randomized, double-blinded trial, 127 adult volunteers were immunized with 15 mu g of rHA0, 15 mu g of rHA0 plus alum, 90 mu g of rHA0, licensed subvirion vaccine, or saline placebo. The rHAO vaccines caused fewer local adverse reactions than did the commercial subvirion preparation. Neutralizing hemagglutinin-specific antibody responses to 15 mu g of rHA0 were comparable to those elicited by licensed vaccine, not enhanced by the addition of alum, and significantly increased by raising the rHA0 dose from 15 to 90 mu g. Compared with placebo recipients, rHA0-vaccinated subjects had significantly lower rates of influenza A (H3N2) virus infection and illness during the epidemic winter season. These results suggest that influenza vaccines containing purified rHA0 may offer an advantage over licensed preparations containing egg-grown antigens by inducing equivalent protective immune responses while being potentially less reactogenic.

引用

页码：1595 / 1599

页数：5

共 15 条

[1]

Prevention and control ofinfluenza: Part i, vaccines, Morb Mortal Wkly Rep, 42, pp. 1-14, (1993)

[2]

Ada G.L., Jones P.D., The immune response to influenza infection, Curr Top Microbiol Immunol, 128, pp. 1-54, (1986)

[3]

Nichol K.L., Lofgren R.P., Gapinski J., Influenza vaccination: Knowledge, attitudes, and behavior among high-risk outpatients, Arch Intern Med, 152, pp. 106-110, (1992)

[4]

Robertson J.S., Bootman J.S., Newman R., Et al., Structural changes in the haemagglulinins which accompany egg adaptation of an influenza a (H1n1) virus, Virology, 160, pp. 31-37, (1987)

[5]

Katz J.M., Naeve C.W., Webster R.G., Host cell-mediated variation in h3n2 influenza viruses, Virology, 156, pp. 386-395, (1987)

[6]

Katz J.M., Webster R.G., Efficacy of inactivated influenza virus (H3n2) vaccines grown in mammalian cells or embryonated eggs, J Infect Dis, 160, pp. 191-198, (1989)

[7]

Murphy B.R., Phelan M.A., Nelson D.L., Et al., Hemagglutinin-specific „ enzyme-linked immunosorbent assay for antibodies to influenza a and b viruses, J Clin Microbiol, 13, pp. 554-560, (1981)

[8]

Treanor J.J., Betts R.F., Evaluation oflive attenuated cold-adapted influenza b/yamagata/16/88 reassortant virus vaccine in healthy adults, J Infect Dis, 168, pp. 455-459, (1993)

[9]

Quinnan G.V., Schooley R., Dolin R., Ennis F.A., Gross P., Gwaltney J.M., Serologic responses and systemic reactions in adults after vaccination with monovalent a/ussr/77 and trivalent a/ussr/77, a/texas/77, b/hong kong/72 influenza vaccines, Rev Infect Dis, 5, pp. 748-757, (1983)

[10]

Margolis K.L., Nichol K.L., Poland G.A., Pluhar R.E., Frequency of adverse reactions to influenza vaccine in the elderly. A randomized, placebocontrolled trial, JAMA, 264, pp. 1139-1141, (1990)

← 1 2 →